Based on the key measurements obtained from MEI Pharma's financial statements, MEI Pharma is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in December. At this time, MEI Pharma's Property Plant And Equipment Gross is relatively stable compared to the past year. As of 11/22/2024, Property Plant Equipment is likely to grow to about 16 M, while Total Stockholder Equity is likely to drop slightly above 32.7 M. Key indicators impacting MEI Pharma's financial strength include:
The financial analysis of MEI Pharma is a critical element in measuring its lifeblood. Investors should not minimize MEI Pharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
18.67 Million
MEI
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Free Cash Flow
Total Cash From Operating Activities
Stock Based Compensation
Depreciation
Change To Inventory
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Retained Earnings
Accumulated Other Comprehensive Income
Short Term Investments
Short Long Term Debt Total
Non Current Liabilities Total
Property Plant And Equipment Net
Non Current Assets Total
Property Plant And Equipment Gross
Property Plant Equipment
Net Tangible Assets
Good Will
Retained Earnings Total Equity
Capital Surpluse
Deferred Long Term Liab
Intangible Assets
Non Currrent Assets Other
Current Deferred Revenue
Net Invested Capital
Net Working Capital
Other Liab
Net Receivables
Non Current Liabilities Other
Short Term Debt
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Income Tax Expense
Cost Of Revenue
Selling And Marketing Expenses
Total Other Income Expense Net
Depreciation And Amortization
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past MEI Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of MEI Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in MEI Pharma's assets may result in an increase in income on the income statement.
MEI Pharma competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what MEI Pharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining MEI Pharma's current stock value. Our valuation model uses many indicators to compare MEI Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MEI Pharma competition to find correlations between indicators driving MEI Pharma's intrinsic value. More Info.
MEI Pharma is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for MEI Pharma is roughly 3.08 . At this time, MEI Pharma's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value MEI Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
MEI Pharma Systematic Risk
MEI Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MEI Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on MEI Pharma correlated with the market. If Beta is less than 0 MEI Pharma generally moves in the opposite direction as compared to the market. If MEI Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MEI Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MEI Pharma is generally in the same direction as the market. If Beta > 1 MEI Pharma moves generally in the same direction as, but more than the movement of the benchmark.
MEI Pharma Thematic Clasifications
MEI Pharma is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in MEI Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MEI Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MEI Pharma growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MEI Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MEI Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of MEI Pharma based on widely used predictive technical indicators. In general, we focus on analyzing MEI Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MEI Pharma's daily price indicators and compare them against related drivers.
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.